First Time Loading...

Forma Therapeutics Holdings Inc
NASDAQ:FMTX

Watchlist Manager
Forma Therapeutics Holdings Inc Logo
Forma Therapeutics Holdings Inc
NASDAQ:FMTX
Watchlist
Price: 20.01 USD Market Closed
Updated: Mar 28, 2024

Intrinsic Value

FMTX price has not been updated for more than 3 months. This may indicate that the stock has been delisted.

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. [ Read More ]

There is not enough data to reliably calculate the intrinsic value of FMTX.

Key Points:
FMTX Intrinsic Value
Base Case
Not Available
Base Case Scenario

Fundamental Analysis

Financials

Balance Sheet Decomposition
Forma Therapeutics Holdings Inc

Current Assets 426.4m
Cash & Short-Term Investments 395.9m
Receivables 15.4m
Other Current Assets 15.2m
Non-Current Assets 48.7m
PP&E 35.9m
Other Non-Current Assets 12.8m
Current Liabilities 33.5m
Accounts Payable 3m
Accrued Liabilities 28.8m
Other Current Liabilities 1.7m
Non-Current Liabilities 27.2m
Other Non-Current Liabilities 27.2m
Efficiency

Earnings Waterfall
Forma Therapeutics Holdings Inc

Revenue
0 USD
Operating Expenses
-191.1m USD
Operating Income
-191.1m USD
Other Expenses
970k USD
Net Income
-190.2m USD

Free Cash Flow Analysis
Forma Therapeutics Holdings Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

FMTX Profitability Score
Profitability Due Diligence

Forma Therapeutics Holdings Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

17/100
Profitability
Score

Forma Therapeutics Holdings Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

FMTX Solvency Score
Solvency Due Diligence

Forma Therapeutics Holdings Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
64/100
Solvency
Score

Forma Therapeutics Holdings Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

FMTX Price Targets Summary
Forma Therapeutics Holdings Inc

There are no price targets for FMTX.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

FMTX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

FMTX Price
Forma Therapeutics Holdings Inc

1M 1M
-
6M 6M
-
1Y 1Y
-
3Y 3Y
-20%
5Y 5Y
-49%
10Y 10Y
-49%
Annual Price Range
20.01
52w Low
N/A
52w High
N/A
Price Metrics
Average Annual Return -13.69%
Standard Deviation of Annual Returns
N/A
Max Drawdown -90%
Shares Statistics
Market Capitalization 957.2m USD
Shares Outstanding 47 860 400
Percentage of Shares Shorted 3.31%

FMTX Return Decomposition
Main factors of price return

What is price return decomposition?

FMTX News

Last Important Events
Forma Therapeutics Holdings Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Forma Therapeutics Holdings Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Forma Therapeutics Holdings Inc Logo
Forma Therapeutics Holdings Inc

Country

United States of America

Industry

Biotechnology

Market Cap

957.2m USD

Dividend Yield

0%

Description

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 166 full-time employees. The company went IPO on 2020-06-16. The firm is focused on the development and commercialization of therapeutics for patients with hematologic diseases and cancers. Its pipeline consists of six product candidates. Its product candidates include etavopivat, FT-7051, Olutasidenib- Acute Myeloid Leukemia IDH1m inhibitor, and Olutasidenib Glioma IDH1m inhibitor. Its lead product candidate, etavopivat, is an oral, once-daily, potentially disease-modifying therapy for the treatment of sickle cell disease (SCD), and other hemoglobinopathies. Its product candidate, FT-7051, is an inhibitor of CREB-binding protein/E1A binding protein p300, or CBP/p300 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Olutasidenib is an oral, selective small molecule investigational agent designed to selectively bind to and inhibit mutated IDH1 enzymes.

Contact

MASSACHUSETTS
Watertown
300 North Beacon Street, Suite 501
+16176791970.0
https://ir.formatherapeutics.com/

IPO

2020-06-16

Employees

166

Officers

Pres & CEO
Mr. Frank D. Lee
Sr. VP & CFO
Mr. Todd E. Shegog
Sr. VP & Chief Technology Officer
Dr. John E. Bishop Ph.D.
Sr. VP & Chief Scientific Officer
Dr. David N. Cook Ph.D.
Head of Investor Relations
Mr. Mario Vincent Corso C.F.A.
Sr. VP, Gen. Counsel & Corp. Sec.
Dr. Jeannette Potts J.D., Ph.D.
Show More
VP of Commercial Strategy & Marketing
Ms. Xuandai Nguyen Ph.D.
Sr. VP & Chief HR Officer
Ms. Linea Aspesi
Sr. VP of Commercial
Mr. Brian Lesser
Sr. VP & Chief Patient Officer
Dr. Ifeyinwa Osunkwo M.D., M.P.H.
Show Less

See Also

Discover More